Yahoo! Finance: Biotechnology Industry News: FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

FDA Accepts Biogen Idec's Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B Mar 4th 2013, 12:30 [Business Wire] - Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of recombinant factor IX Fc fusion protein for the treatment of hemophilia B and granted the company a standard review timeline.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions